Hollis-Eden Pharmaceuticals and the Cystic Fibrosis Foundation to collaborate on clinical development of HE2000 in cystic fibrosis.

(From Chemical Business NewsBase - Press Release)

Hollis-Eden Pharmaceuticals Inc (Hollis-Eden) and Cystic Fibrosis Foundation Therapeutics Inc announced a collaboration agreement to study HE2000 (Immunitin), one of Hollis Eden's investigational immune regulating hormones (IRHs) in a Phase I/II clinical trial for the treatment of cystic fibrosis (CF). Cystic Fibrosis Foundation Therapeutics will award about $1.7 M in funding toward the clinical development of the investigational drug candidate. Based on Hollis-Eden's data regarding the anti-inflammatory effects and attenuation of opportunistic infections in early clinical studies in patients with …